ArticleDigestive diseases and sciences2025
Differential Prognostic Impact of Tumor Burden Score on Hepatocellular Carcinoma Patients with Variable Physical Performance Status.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPerformance status (PS) plays a crucial role in prognostic prediction for patients with hepatocellular carcinoma (HCC). The extent of tumor burden is also a major survival determinant. Recently, tumor burden score (TBS) was proposed to evaluate the extent of tumor involvement, but the interaction between TBS and PS has not been evaluated. We aimed to assess the prognostic role of TBS in HCC patients with variable PS.
methodsA large cohort of 4185 treatment-naïve HCC patients were retrospectively analyzed. The multivariate Cox proportional hazards model was used to determine the independent predictors associated with survival.
resultsPatients with poorer PS had significantly higher TBS at baseline. In the Cox model, older age, lower serum albumin level, higher serum bilirubin, creatinine and α-fetoprotein levels, presence of ascites, presence of vascular invasion, PS 1-2, PS 3-4, and medium TBS and high TBS were independently associated with increased mortality in the entire cohort (p < 0.001). In subgroup analysis stratified by PS, TBS was able to predict long-term survival in patients with PS 0 in the multivariate model. For patients with PS 1-2, the trend was significant only in those with high TBS (p < 0.001); in patients with PS 3-4, TBS was not significantly associated with survival (p > 0.05).
conclusionsTBS is a feasible prognostic surrogate for HCC and can well discriminate long-term survival in patients with good PS. Our findings demonstrate that TBS has a differential prognostic impact on HCC and may play a distinct role in outcome prediction for patients with variable PS.
Indexed as
Identifiers
40153238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.